Printer Friendly

SIBIA NAMES FORMER WYETH-AYERST EXEC AS SENIOR DIRECTOR OF PHARMACOLOGY AND PRECLINICAL DEVELOPMENT

 SIBIA NAMES FORMER WYETH-AYERST EXEC AS SENIOR
 DIRECTOR OF PHARMACOLOGY AND PRECLINICAL DEVELOPMENT
 LA JOLLA, Calif., Oct. 22 /PRNewswire/ -- SIBIA Inc., a San Diego-area biopharmaceutical company, announced today that it has named G. Kenneth Lloyd, Ph.D., as senior director of pharmacology and preclinical development. Lloyd was formerly assistant vice president of research and head of Central Nervous System (CNS) Discovery for Wyeth-Ayerst. Lloyd will be a key member of SIBIA's research management and will play a vital role in the development of its CNS therapeutic products, according to William T. Comer, Ph.D., president and chief executive officer.
 "We are very pleased to have someone of Lloyd's caliber joining the company," Comer said. "With nearly 20 years of pharmaceutical industry experience, Dr. Lloyd has taken candidate drugs from discovery through clinical trials to commercial launch. We feel he will be a strong contributor to SIBIA's development and will have an immediate impact on our programs."
 Michael M. Harpold, Ph.D., vice president, research, said, "Dr. Lloyd's extensive background in CNS pharmacology and his experience in successfully coordinating the activities of large research teams will be invaluable to SIBIA. He will be instrumental in characterizing and evaluating the promising compounds that result from our Advanced Receptor and Protease Nexin technologies and directing them into clinical trials."
 Before joining Wyeth-Ayerst in 1990, Lloyd held various research management positions at Synthelabo SA in France, culminating with six years as associate director, biology, with responsibility for CNS, Cerebrovascular, Bronchopulmonary, Gastrointestinal and Inflammation research. Prior to Synthelabo, Lloyd was a member of the Department of Psychiatry and Pharmacology at the University of Toronto and was on the research staff at Hoffman LaRoche in Basel, Switzerland. Lloyd has a Ph.D. in Pharmacology from the University of Toronto and a master of science in biochemistry from McGill University.
 SIBIA's proprietary Advanced Receptor Technology is based on the use of cloned human brain receptor subtype genes (expressed in mammalian cell lines) as functional assays in an in vitro assay format to identify and develop promising new candidate drugs. The company is concentrating its efforts on identifying drugs acting at three specific classes of neurotransmitter receptors including excitatory amino acid (EAA) receptors, neuronal nicotinic acetylcholine (ACh) receptors and neuronal voltage-dependent calcium channels (VDCCs). In 1992, the company entered into corporate partnerships with Eli Lilly and Co. and with Ciba-Geigy Ltd. to discover and develop novel CNS drugs that act at specific VDCCs and EAA receptors, respectively.
 SIBIA's Protease Nexin Technology centers on molecular and cellular models and assays for proteolytic enzymes and enzyme inhibitors involved in amyloid precursor protein (APP) processing, as well as the molecules PN-1 and PN-2, all of which may be involved in neurodegenerative processes. SIBIA is pursuing the discovery and development of therapeutic drugs for Alzheimer's disease and related conditions with this technology and is developing a diagnostic assay for Alzheimer's diseases as well.
 SIBIA Inc. is a privately held pharmaceutical company founded in 1981 by the Salk Institute for Biological Studies. The company is developing novel diagnostic and therapeutic products for neurodegenerative conditions such as Alzheimer's disease, Parkinson's disease, epilepsy and stroke, based on advanced technology that provides novel approaches to the processes underlying these disorders.
 -0- 10/22/92
 /CONTACT: Michael Dunn of SIBIA, 619-452-5892; or Linda Seaton of Keatinge/Seaton Communications, 619-625-2100, for SIBIA/ CO: SIBIA Inc. ST: California IN: MTC SU: PER


JL-LS -- SD003 -- 3347 10/22/92 09:16 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 22, 1992
Words:572
Previous Article:RYDER EARNINGS UP SHARPLY IN THIRD QUARTER
Next Article:AZTAR REPORTS STRONG THIRD QUARTER
Topics:


Related Articles
LIDAK PHARMACEUTICALS APPOINTS NEW BOARD MEMBER
HASSAN NAMED GROUP V.P./GLOBAL PHARMACEUTICALS OF AMERICAN HOME PRODUCTS CORPORATION; ESSNER SUCCEEDS HASSAN AS WYETH-AYERST PRESIDENT
PROCYTE CORPORATION NAMES TWO NEW CORPORATE OFFICERS
THERAPEUTIC DISCOVERY CORP. APPOINTS DIRECTOR
THERAPEUTIC DISCOVERY APPOINTS NEW BOARD MEMBER
ROBERT LEVY, M.D. JOINS GENETICS INSTITUTE BOARD; BERNARD CANAVAN, M.D. RESIGNS
DAVID DODD NAMED PRESIDENT AND CEO OF SOLVAY PHARMACEUTICALS, INC.
AMERICAN HOME PRODUCTS ANNOUNCES CORPORATE ORGANIZATIONAL CHANGES
DR. GAIL E. GILLENWATER NAMED VICE PRESIDENT OF CLINICAL AND REGULATORY AFFAIRS OF VYREX CORPORATION
American Home Products Announces Organizational Changes at Its Wyeth-Ayerst Division

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters